PATENT CLAIM ANALYSIS

Application Number: 16103865
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2018-12
Patent Classification: ["424", "135100"]

Abstract:
Provided herein are combinations that include an HDACi and a PD-1 inhibitor that are useful for treating cancer, including reducing and/or preventing cancer metastasis. The combination is also useful for treating cancer that has been previously treated with a PD-L1 inhibitor.

Claim (Index 22):
A method for treating melanomain a subject, comprising administering to said subject a therapeutically effective amount of a compound of the following formula: in combination with nivolumab.

Metadata:
- Claim Count in Document: 32.0
- Percentile: 96.0
- Lexical Diversity: 1.33333
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15592988', '15593915', '15592929', '15748284', '15480992']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7173658452013024
- 35 USC 102 Novelty (BERT): 0.5369461844302378
- Combined Prediction Score: 0.699323879124196
- Mean Citation Score: 230.001678
- Max Citation Score: 385.25516
- Similarity Product: 249.04660723208903

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test